| serum hepatitis virus | The type species of the genus orthohepadnavirus which causes human hepatitis b and is also apparently a causal agent in human hepatocellular carcinoma. The dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. (12 Dec 1998) |
|---|---|
| short incubation hepatitis | A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom. Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis. (05 Mar 2000) |
| NANB hepatitis | Hepatitis caused by two or more infectious agents not detectable by methods that reveal the presence of hepatitis viruses A and B; one cause, now called type C hepatitis has been identified; may follow blood transfusion and is often seen in chronic renal dialysis patients. Synonym: NANB hepatitis. (05 Mar 2000) |
| neonatal hepatitis | Hepatitis in the neonatal period presumed to be due to a variety of causes, chiefly viral; characterised by direct and indirect bilirubinaemia, hepatocellular degeneration, and appearance of multinucleated giant cells; may be difficult to distinguish from biliary atresia, but is more likely to end with recovery, although cirrhosis may develop. Synonym: giant cell hepatitis. (05 Mar 2000) |
| subacute hepatitis | <pathology> This is a form of continuing liver inflammation that results in liver cell death. Causes include viral infection (hepatitis D, hepatitis B, hepatitis C), autoimmune disease, drug ingestion or metabolic causes. Chronic active hepatitis will lead to hepatic failure and death in a small percentage of these patients. (27 Sep 1997) |
| non-A, non-B hepatitis | Hepatitis caused by two or more infectious agents not detectable by methods that reveal the presence of hepatitis viruses A and B; one cause, now called type C hepatitis has been identified; may follow blood transfusion and is often seen in chronic renal dialysis patients. Synonym: NANB hepatitis. (05 Mar 2000) |
| non-A, non-B hepatitis virus | Term used to group any of a number of viruses, other than A or B, which cause hepatitis in humans. (05 Mar 2000) |
| non-A, non-B, non-C hepatitis | Hepatitis caused by viral organisms other than hepatitis viruses A, B or C. (05 Mar 2000) |
| suppurative hepatitis | Hepatitis with abscess formation; often amoebic in origin. (05 Mar 2000) |
| delta hepatitis | Acute or chronic hepatitis caused by the hepatitis delta virus, a defective RNA virus requiring HBV for replication. The acute type occurs in two forms: 1) coinfection, the simultaneous occurrence of hepatitis B virus and hepatitis delta virus infections, which usually is self-limiting; 2) superinfection, the appearance of hepatitis delta virus infection in a hepatitis B virus carrier, which often leads to chronic hepatitis The chronic type appears to be more severe than other types of viral hepatitis. Synonym: delta hepatitis, hepatitis D. (05 Mar 2000) |
| drug-induced hepatitis | <hepatology, pathology> Inflammation and hepatocellular damage of the liver that is caused by a drug. Some medications may cause inflammation of the liver as a drug side effect or drug toxicity. Drugs that are known to cause hepatitis include acetaminophen, isoniazid, halothane, methyldopa, erythromycin and oral contraceptives. (27 Sep 1997) |
| duck hepatitis virus | A DNA virus of the genus Hepadnavirus, in the family Hepadnaviridae, causing virus hepatitis of ducks. (05 Mar 2000) |
| duck viral hepatitis | An acute, highly contagious disease of young ducklings caused by an enterovirus and characterised by lethargy, spasmodic paddling and rapid death. (05 Mar 2000) |
| immunization, hepatitis a | When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. (12 Dec 1998) |
| immunization, hepatitis b | Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection. (12 Dec 1998) |
| hepatitis B core a. |
a core protein antigen of the hepatitis B virus present inside complete virions (Dane particles) and in the nuclei of infected hepatocytes, indicating the presence of replicating hepatitis B virus; the antigen is not present in the blood of infected individuals, but anti-HBc antibodies appear during the acute infection; they do not protect against reinfection.
출처: www.mercksource.com/pp/us/cns/cns_health_library.j...
|
|---|---|
| hepatitis B e a. |
an antigen of hepatitis B virus sometimes present in the blood during acute infection, usually disappearing afterward but sometimes persisting in chronic disease. Anti-HBe antibodies appear transiently during convalescence; they do not protect against reinfection.
출처: www.mercksource.com/pp/us/cns/cns_health_library.j...
|
| hepatitis B immune g. |
[USP] a specific immune globulin derived from plasma of human donors with high titers of antibodies against hepatitis B surface antigen (HBsAg); used for postexposure prophylaxis following contact with HBsAg-positive materials, also administered to infants of HBsAg-positive mothers.
출처: www.mercksource.com/pp/us/cns/cns_health_library.j...
|
| hepatitis B surface a. |
a coat protein antigen of the hepatitis B virus present on complete virions (Dane particles) and smaller spherical and filamentous particles circulating in the blood of individuals with active or chronic infections, being first detectable several weeks prior to clinical disease and peaking with the appearance of symptoms. Anti-HBs antibodies appear in the blood in late convalescence and are protective against reinfection. Originally called Australia or Au antigen because it was first found in an Australian aborigine; also formerly called hepatitis-associated a. (HAA) and serum hepatitis (SH) a. See hepatitis B vaccine inactivated and hepatitis B vaccine (recombinant), under vaccine.
출처: www.mercksource.com/pp/us/cns/cns_health_library.j...
|
| hepatitis B v. |
a virus of the genus Orthohepadnavirus that is the etiologic agent of hepatitis B.
출처: www.mercksource.com/pp/us/cns/cns_health_library.j...
|